What is the utility of immunotherapy in management of malignant peripheral nerve sheath tumors?
1 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
The correct answer would be "unknown" or "TBD". Enrollment on clinical trials, even broad phase 1 trials, would be encouraged in cases where SOC therapy has failed.
